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Introduction
Community-acquired pneumonia (CAP) is the leading cause of 
death among those with an infectious disease [1].  It accounts for 
hospitalization, high mortality and increased health care cost 
[2].  Mortality due to CAP ranges from 3% for outpatients up to 
50% for patients admitted in the ICU [1].
Of the majority of patients with CAP treated in an outpatient 
setting, only a small proportion require hospitalization [3]. 
Following hospitalization, the optimal empiric antimicrobial 
treatment needs to be selected based on cost-effectiveness, 
spectrum of activity, local resistance patterns, and possible 
toxicities.  The empiric regimen should have activity against 
Streptococcus pneumoniae and atypical pathogens like 
Chlamydia pneumoniae, Legionella pneumophila and 
Mycoplasma pneumoniae [4].
Choosing an appropriate empiric antibiotic regimen plays a 
crucial role in determining the clinical success of hospitalized 
patients with CAP.  The 2007 Infectious Diseases Society of 
America (IDSA)/American Thoracic Society (ATS) guidelines 
for CAP recommend either a respiratory fluoroquinolone 
or a β-lactam plus a macrolide for hospitalized patients [5]. 
Retrospective studies have documented decreased mortality, 
length of stay and less re-admission rate when patients are 
treated with guideline-concordant antimicrobial therapy [6, 7]. 
Studies leading up to and after the 2007 IDSA/ATS guidelines, 
have reached varying conclusions regarding superiority of 
one regimen over another.  Some studies favored a β-lactam 
plus a macrolide over fluoroquinolone monotherapy, whereas 
other studies favored fluoroquinolone monotherapy [2, 8-12]. 
While other studies documented similar outcomes in patients 
receiving either regimen [13-16]. 
A study is needed that includes guideline-concordant 
antimicrobial regimens, identification of CAP with clinical, 
rather than with billing criteria, and includes a “real-world” 
population.  It should also be large and enroll consecutive 
patients in an entire city over a long period.  The present study 
sought to have these characteristics.  
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Abstract
Background: Current guidelines recommend a β-lactam plus a macrolide or fluoroquinolone 
monotherapy as the initial empiric antibiotic therapy for treatment of patients hospitalized with 
community-acquired pneumonia (CAP).  Multiple studies have shown different results comparing 
the two regimens for the treatment of CAP.  Our objective, in a city-wide prospective study, was to 
compare outcomes among hospitalized patients with CAP who received empiric treatment either with 
a β-lactam plus a macrolide or fluoroquinolone monotherapy. 
Methods: This was a propensity score matched case-control study. It was a prospective population-
based cohort study of all hospitalized adults with CAP.  Patients were divided into two groups and 
propensity score matched based on empiric therapy; a β-lactam plus a macrolide compared to 
fluoroquinolone monotherapy.  Study outcomes included time to clinical stability, length of stay, and in-
hospital, 30-day and 1-year mortality.  Stratified Cox proportional hazards regression was performed 
to analyze continuous variable differences between groups, and conditional logistic regression was 
performed to analyze dichotomous variable differences in mortality.
Results: An association was not found between the two groups for time to clinical stability (aHR: 
1.06; 95% CI: 0.93-1.22), length of stay (aHR: 1.14; 95% CI: 0.99-1.32) or mortality.
Conclusions: The present study failed to demonstrate differences in short or long-term outcomes 
for hospitalized CAP patients treated with either a β-lactam plus a macrolide or fluoroquinolone 
monotherapy.  Therefore, our study does not support the superiority of one treatment over another.
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Objective
This study sought to define whether clinical outcomes were 
similar or different for hospitalized patients with CAP based on 
the use of a β-lactam plus a macrolide versus fluoroquinolone 
monotherapy. 
Methods
Study design and study population 
This was a propensity score matched case-control study; a 
prospective population-based cohort study of hospitalized 
adult residents of a metropolitan city in the midwest region 
of the United States with CAP from all 9 hospitals in the city 
[21].  Patients were analyzed from June 1, 2014, to May 31, 
2016.  Patients meeting inclusion criteria were split into two 
antibiotic treatment arms: either a β-lactam plus a macrolide 
or fluoroquinolone monotherapy. Demographic and clinical 
data were collected for each patient.  The source reviewed for 
laboratory test results were blood, sputum, tracheal aspirate, 
bronchoalveolar lavage, urine, nasopharynx and oropharynx.
Inclusion Criteria
A diagnosis of CAP required radiographic criteria, clinical 
criteria and the initiation of antimicrobials within 24 hours of 
admission.  A new pulmonary infiltrate on imaging (computed 
tomography or chest radiograph) was required at  time of 
admission to the hospital.  Each patient had to have at least one 
of the following signs or symptoms of CAP: new or increased 
cough, fever >37.8°C (100.0°F) or hypothermia <35.6°C 
(96.0°F) or a change in serum white blood cells (leukocytosis 
with >11,000 cells/mm3, left shift with >10% band forms/µL, 
or leukopenia with <4,000 cells/mm3).  Patients were eligible 
for inclusion if they had empiric therapies with either 1) a 
β-lactam plus a macrolide, or 2) fluoroquinolone monotherapy. 
An organism identified in the laboratory was not a criterion for 
inclusion.
Propensity score matching
Patient groups were matched using propensity scores with 
a nearest neighbor algorithm, with a caliper of 0.20 standard 
deviations to prevent poor matches.  Variables included in the 
creation of the propensity score were age, sex, race, hospital 
attended, ICU admission, nursing home residency, altered 
mental status on admission, serum sodium on admission and 
a history of the following: neoplastic disease, congestive heart 
failure, stroke, renal disease, diabetes or, chronic obstructive 
pulmonary disease. 
Group 1 included patients who received a β-lactam and a 
macrolide given as combination therapy during the first 24 hours 
of hospitalization.  Group 2 included patients who received 
a fluoroquinolone given as monotherapy during the first 24 
hours of hospitalization.  Macrolides included azithromycin, 
clarithromycin or erythromycin.  β-lactams included 
amoxicillin, amoxicillin-clavulanate, ampicillin, ampicillin-
sulbactam, cefaclor, cefazolin, cefepime, cefixime, cefoperazone, 
cefotaxime, cefotetan, cefpodoxime, ceftazidime, ceftriaxone, 
cefuroxime, cephalexin, imipenem-cilastin, meropenem, 
nafcillin, penicillin G, piperacillin and piperacillin-tazobactam. 
Fluoroquinolones included ciprofloxacin, levofloxacin and 
moxifloxacin.
Study Outcomes
Study outcomes included time to clinical stability, length of stay 
and mortality.  Time to clinical stability was defined as the day 
when the patient met the following four criteria: improvement in 
cough and shortness of breath, lack of fever for at least 8 hours, 
improved leukocytosis (normal or decreased at least 10% from 
the previous day) and toleration of oral intake with adequate 
gastrointestinal absorption.  Patients were prospectively 
evaluated daily for the first seven days of hospitalization to 
determine when time to clinical stability was reached.  Length of 
stay was defined in days from admission to discharge.  Patients 
hospitalized for more than 14 days were censored at 14 days in 
an effort to record length of stay related to CAP.  Mortality was 
defined as death by any cause during hospitalization at 30 days 
and 1 year. 
Statistical Analysis
Descriptive statistics were performed, with comparisons 
between groups analyzed by using a χ² test or Fisher’s exact 
test for categorical data (e.g., male versus female) and the 
Wilcoxon-Mann-Whitney U test for continuous data (e.g., 
temperature).  Cox proportional hazards regression and 
the log-rank test were performed to analyze differences 
between groups with and without accounting for potentially 
confounding variables, respectively.  Logistic regression was 
performed to analyze differences in mortality.  Variables were 
selected for multivariate analysis if they contained a P-value 
of less than 0.20 in a univariate Cox proportional hazards or 
logistic regression.  A P-value of less than 0.05 was considered 
statistically significant.  Differences in outcomes adjusting for 
propensity score matching were analyzed using stratified Cox 
proportional hazards regression for time to clinical stability 
and length of stay.  Conditional logistic regression was used for 
mortality.  
Results
Patients receiving a β-lactam plus a macrolide were matched 
to patients receiving fluoroquinolone monotherapy with 706 in 
each group (Figure 1).  The mean age of patients was 67 years. 
Characteristics of hospitalized patients in each group are in 
Table 1.  After propensity score matching, the hematocrit was 
the only variable significantly differing between groups.  The 
number of organisms that were identified in patients with a 
positive test for a pathogen is in Table 2. 
The percentage of patients who reached clinical stability 
in the first seven days for each group were similar (Figure 
2).  The median time to clinical stability was two days for 
each group, which was not significantly different; (adjusted 
hazard ratio (aHR) 1.06; 95% confidence interval (CI) 0.93-
1.22).  The percentage of patients discharged in the first 
two weeks for each group were also similar (Figure 3). 
The median length of stay was 4 days in each group, which was 
not significantly different; (aHR1.14; 95% CI 0.99-1.32).
In-hospital mortality, 30-day mortality and 1-year mortality 
were also not significantly different in the β-lactam plus 
macrolide group and the fluoroquinolone group (Figure 4). 
In-hospital mortality was in 15 patients versus 16, respectively; 
(adjusted Odds Ratio (aOR) 1.64; 95% CI; 0.54-4.91).  The 30-
day mortality was in 38 patients versus 33 patients, respectively; 
(aOR 0.97; 95% CI 0.48, 1.94).  One-year mortality was in 129 
patients versus 126 patients, respectively; (aOR 1.02; 95% CI 
0.72-1.44). 
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Patients No. 706 706   
Demographics 
Male sex, No. (%) 318 (45.0) 309 (43.8) 0.668 
Black race, No. (%) 151 (21.4) 149 (21.1) 0.948 
Age, Median years [IQR] 67 [54, 79] 67 [56, 78] 0.745 
Comorbidities  Frequency (%) P-value 
COPD, No. (%) 358 (50.7) 368 (52.1) 0.632 
Current smoker, No. (%) 247 (35.0) 247 (35.0) >0.999 
Diabetes mellitus, No. (%) 208 (29.5) 196 (27.8) 0.517 
Congestive heart failure, No. (%) 179 (25.4) 200 (28.3) 0.230 
Renal disease, No. (%) 154 (21.8) 151 (21.4) 0.897 
Neoplastic disease, No. (%) 71 (10.1) 71 (10.1) >0.999 
Stroke, No. (%) 60 (8.5) 71 (10.1) 0.359 
HIV disease, No. (%) 15 (2.1) 12 (1.7) 0.698 
Physical Exam Findings Median [IQR] P-value 
Heart rate, Beats/Minute [IQR] 104 [92, 117] 104 [91, 116] 0.446 
Respiratory rate, Breaths/Minute 
[IQR] 
22 [20, 26] 22 [20, 25] 0.231 
Systolic blood pressure, mmHg 
[IQR] 
119 [104, 136.8] 121 [104, 139] 0.176 
Diastolic blood pressure, mmHg 
[IQR] 
59 [51, 69] 60 [52, 71] 0.224 
Temperature °Celsius, [IQR] 37.2 [36.8, 37.8] 37.1 [36.8, 
37.7] 
0.089 
Laboratory Findings Median [IQR] P-value 
Hematocrit, median % [IQR] 36.5 [32.4, 40.5] 37.4 [33, 41.1] 0.017 
Serum bicarbonate, median 
mEq/L [IQR] 
26 [24, 29] 26 [24, 29] 0.357 
Blood urea nitrogen, mg/dL [IQR] 17 [12, 25] 18 [12, 25] 0.428 
Serum glucose, mg/dL [IQR] 139 [113, 197] 139 [113, 179] 0.450 
Serum sodium, mEq/L [IQR] 137 [134, 139] 137 [134, 140] 0.297 
Severity of Disease on 
Admission 
Frequency (%) P-value 
Need for intensive care, No. (%) 50 (7.1) 53 (7.5) 0.838 
Altered mental status, No. (%) 58 (8.2) 72 (10.2) 0.231 
Need for vasopressors, No. (%) 1 (0.1) 4 (0.6) 0.370 
Need for ventilatory support, No. 
(%) 
51 (7.2) 51 (7.2) >0.999 
PSI risk class IV or V, No. (%) 328 (46.5) 337 (47.7) 0.670 
 
Abbreviations: COPD, Chronic obstructive pulmonary diseases; 
HIV, Human immunodeficiency virus infection; 
IQR, Interquartile range; 
PSI, Pneumonia severity index 
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Table 2 Micro-organisms identified for patients* in each group.




Streptococcus pneumoniae 26 16 
Pseudomonas aeruginosa 9 3 
MRSA 6 5 
MSSA 5 4 
Staphylococcus – coagulase-negative  6 4 
Klebsiella pneumoniae 2 2 
Streptococcus pyogenes 2 1 
Other Streptococci  5 2 
Moraxella catarrhalis 0 3 
Atypical Pathogens 
Mycoplasma pneumoniae 2 2 
Legionella spp. 1 0 
Viruses 
Influenza A 2009 H1N1, A H3, 
Untyped, B 8 15 
Haemophilus influenzae, 
parainfluenzae 7 8 
Human metapneumovirus 7 8 
Rhinovirus/Enterovirus 7 16 
Parainfluenza virus 1,3,4 6 4 
Corona virus HKU1, NL63, OC43 6 3 
Respiratory syncytial virus A, 
Unknown type 3 4 
Mycobacteria  
Nontuberculous mycobacteria  0 1 
Fungi 
Aspergillus spp. 0 2 
Candida tropicalis  0 1 
Saprophytic fungus 1 0 
Other 
Enterobacter spp. 4 0 
Escherichia coli 2 4 
Corynebacterium species 1 2 
Propionibacterium acne 1 0 
Enterococcus faecalis  1 0 
Micrococcus luteus 0 1 
Acinetobacter spp. 1 0 
Achromobacter xylosoxidans 1 0 
Serratia spp. 1 0 
Citrobacter spp. 0 1 
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-resistant 
Staphylococcus aureus  
*  Some patients had more than one organism identified. 
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Figure 2 Kaplan – Meier estimates for time to clinical stability for each antibiotic group hospitalized for CAP.
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Figure 4 Mortality for each antibiotic group hospitalized for CAP.
Figure 3 Kaplan – Meier estimates for length of stay for each antibiotic group hospitalized for CAP.
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Discussion
The present study showed equivalent outcomes in hospitalized 
patients with CAP who were treated with a β-lactam plus a 
macrolide compared to fluoroquinolone monotherapy.  The 
findings do not favor one treatment regimen over another.  
Multiple studies have been published showing either improved 
outcomes with one regimen over another or equivalence. 
The following studies found similar outcomes with either a 
β-lactam plus a macrolide or a fluoroquinolone alone.  Several 
randomized clinical trials reported equal clinical efficacy 
among both treatment groups in non-ICU CAP patients [13, 14, 
20, 22, 23].  In one of these randomized studies, 236 patients 
were randomized into one of two treatment groups.  The 
clinical success rate was defined as a resolution of signs and 
symptoms of CAP, which was 94.1% in the levofloxacin group 
and 92.3% in the ceftriaxone plus azithromycin group (95% 
CI, -10.20 to 6.58)[14].  A meta-analysis of patients treated 
with guideline-concordant antibiotics reported no difference 
in mortality when patients were treated with a β-lactam 
plus a macrolide (5.3%  patients) compared to a respiratory 
fluoroquinolone (5.8% patients); (RR 1.17; 95% CI, 91–1.50; 
P = 0.22) [24].  A retrospective study of a large data set from 
Medicare and Medicaid services compared mortality data of 
27,330 CAP patients.  In patients stratified by ICU admission 
and initial antimicrobial treatment, 30-day mortality among 
non-ICU patients treated with a cephalosporin plus a macrolide 
compared to those who received fluoroquinolone monotherapy 
had similar mortality (RR 0.9; 95% CI 0.78-1.04; P=0.161) [25]. 
These studies were in concordance with the present study.
In contrast, several studies are discordant to the present study 
and favor one regimen over another.  First, there have been 
studies favoring fluoroquinolone use.  One randomized study 
documented earlier resolution or improvement in signs and 
symptoms among patients who received a fluoroquinolone [9]. 
In another randomized study, 628 CAP patients with varying 
severity reported statistically significant higher clinical success 
rates in a moxifloxacin treatment group, bacteriologic success 
and one day shorter time to resolution of fever and duration of 
hospitalization [9].  There were also fewer deaths (nine (3%) 
versus 17 (5%)), and less serious adverse events (38 (12%) versus 
53 (16%)) in the moxifloxacin group than in the comparator 
group.  Other studies have shown less serious side effects 
among patients who received a fluoroquinolone for CAP [9, 12]. 
Finally, a meta-analysis of 23 randomized trials reported that a 
fluoroquinolone was more effective in resolving CAP signs and 
symptoms than treatment with a combination of a β-lactam and 
a macrolide among CAP patients with mild to moderate severity 
(OR 1.39; 95% CI 1.02–1.90) [27]. 
Second, there have also been  studies favoring a β-lactam plus a 
macrolide over fluoroquinolone monotherapy.  A retrospective 
study of 515 hospitalized patients with CAP documented 
significantly lower mortality at 14 days and 30 days among 
patients with a pneumonia severity index (PSI) risk class 
V treated with a β-lactam plus a macrolide as compared to 
fluoroquinolone monotherapy [2].  In an observational study 
of 270 CAP patients hospitalized in the ICU with shock, a 
cephalosporin plus a macrolide was associated with significantly 
higher 28-day survival compared to fluoroquinolone 
monotherapy (aHR, 1.69; 95% CI, 1.09-2.60; P = .01) [28]. 
A variety of factors may explain the superiority of one therapy 
over another.  Some of these factors are not necessarily 
related to antimicrobial activity.  Three reasons other than 
antimicrobial activity that may encourage or preclude one 
from prescribing an antimicrobial other than the outcomes we 
measured include oral bioavailability and the implication of 
earlier discharge [8], the risk for isolating a multidrug-resistant 
organism [29-31], and a drug’s immunomodulatory properties 
[32-33].  Immunomodulation may benefit patients with 
CAP by suppressing pro-inflammatory cytokines, interfering 
attachment of pathogens to respiratory epithelial cells and by 
favoring apoptosis over necrosis in the presence of neutrophils 
[32]. 
One of the strengths of the present study is that it was a 
population-based study with a large sample size including 
multiple patient populations with CAP.  The definition for CAP 
in this study was based on clinical criteria rather than billing 
information. Compared to similar studies, the present study 
stands out because it analyzed comprehensive outcomes for 
early- and late-term outcomes.  Time to clinical stability, length 
of stay and three periods of mortality were evaluated.  The 
present study also has limitations: only penicillin sensitivity 
information for S. pneumoniae and vancomycin sensitivity 
information for Staphylococcus aureus was collected.  No 
specific antibiotic resistance data for other isolated pathogens 
were included in this study.  During the enrollment period, a 
few patients were not enrolled due to refusal by the patient, the 
family or the admitting physician. 
In conclusion, the present study did not show a significant 
difference in time to clinical stability, length of stay or mortality 
when comparing a β-lactam plus a macrolide to fluoroquinolone 
monotherapy.  Hence, our study supports the recommended 
IDSA/ATS guidelines for the treatment of patients with CAP 
recommending either regimen for hospitalized patients: either a 
β-lactam plus a macrolide or fluoroquinolone monotherapy. 
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